A Study of Second-line Treatment With Apatinib After TACE in Advanced Hepatocellular Carcinoma Patients

Inclusion Criteria: * Patients with a histologic or cytologic diagnosis of hepatocellular carcinoma * Have progressed after systematic chemotherapy/target therapy, or cannot tolerated with first-line treatment * The previous chemotherapy and the present trial registration must be at least 2 weeks apart. And they must have recovered from any toxicity of a previous chemotherapy * Patients with Child Pugh Class A \& B disease are eligible for the study * Patients with Barcelona Clinic Liver Cancer stage B or C are eligible for the study * Eastern Cooperative Oncology Group performance score (PS): 0-2 * Life expectancy of at least 12 weeks * Hepatitis B virus DNA\<2000 IU/ml * Adequate organ function meeting the following: * Bone marrow: absolute neutrophil count ≥1.5×109/L (1500/mm3); platelet ≥ 75×109/L; hemoglobin ≥9 g/dL * Liver: Serum bilirubin ≤ 1.5 ×ULN, AST and ALT ≤ 5 ×ULN, ALB ≥ 29 g/L * Kidney: Cr ≤1.5 ×upper limit of normal * Within 7 days prior to the start of therapy, women of child-bearing potential must undergo a pregnancy test, which must be negative; men of child-bearing potential: contraceptive measures must be adopted during treatment and within 8 weeks afterward * Subjects who understand and voluntarily signed a written informed consent form Exclusion Criteria: * Previous locoregional therapy within 4 weeks prior to enrollment * Diagnosed with cholangiocellular carcinoma, mixed cell carcinoma and fibrolamellar hepatocellular carcinoma * History of other malignancy within 5 years except for non-melanoma skin cancer, cervix in situ carcinoma * Prepared for liver transplantation * Patients with contraindications (active bleeding, ulcers, intestinal perforation, intestinal obstruction, within 30 days after major surgery, uncontrolled high blood pressure medication, III-IV level cardiac insufficiency, severe liver and kidney dysfunction) * A previous history of Interstitial pulmonary disease, drug-induced interstitial disease, radiation pneumonitis requiring hormonal therapy or active interstitial lung disease with any clinical evidence * Use of CYP3A4 inhibitor within 7 days or CYP3A4 inducer within 12 days prior to enrollment * Patients with central nervous system metastases or brain metastasis * Previous definite diagnosis of neuropsychiatric disturbances, including epilepsy or dementia * Pregnant or lactating women * Patients with bone metastasis received palliative radiation within 4 weeks prior to enrollment